In p53 gene-based cyclotherapies, the apoptosis of mutp53 cancer cells can be specifically achieved using low doses of p53 gene activators, such as nutlin-3 and actinomycin D, without affecting the cell cycle in normal cells carrying wtp53 [174]. The gene discussed is TP53; the disease is cancer.